All News

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients with relapsed or refractory follicular lymphoma.

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and oncology medicines, with construction beginning in 2025 and operations slated for 2027.

Attorney General Paxton argues that the company’s programs and offerings were essentially bribes and resulted in millions in dollars charged to the state’s Medicaid program.

Monica Seles partners with argenx to raise awareness for Myasthenia Gravis, sharing her journey to empower and support those affected by the condition.

The specialty medication platform earned a spot in the top 15% of the list.

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet medical needs in oncology.

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

Vor Bio appoints Dallan Murray as chief commercial officer, leveraging his extensive experience to drive commercialization and growth strategies for innovative therapies.

The urology MSO will become part of The Specialty Alliance.

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab significantly reduces disease activity and shows a favorable safety profile in adults with active Sjögren’s disease.

The journal is standing by the study, which looked into the safety of vaccines that have aluminum ingredients.

Accelerated approval was based on results from the Phase Ib Beamion-LUNG 1 trial (NCT04886804), which showed a 75% objective response rate in patients with unresectable or metastatic non-squamous non-small cell lung cancer treated with Hernexeos.

Vinay Prasad returns to lead the FDA's CBER after leaving in late July.

GLP-1 medication users must consult physicians before surgery to mitigate anesthesia risks and ensure safe pre-operative practices.

Gene Mack, CEO of Gain Therapeutics, outlines the company’s strategic approach to advancing GT-02287 through potential collaborations and financing options as they await critical Parkinson’s disease trial data.

Radella Pharmaceuticals reveals promising Phase 1b trial results for MD-18, showcasing significant weight loss and cardiometabolic health improvements.

Results from the Phase III CONVOKE trial (NCT05838625) showed that CT-155 demonstrated a favorable safety profile consistent with previous studies in patients with schizophrenia.

Secretary Kennedy explained that nearly $500 million in contracts will be canceled.

The talks are a result of the MFN order, which seeks to make US drug prices match lower prices in international markets.

A new two-phase initiative aims to streamline facility approvals, reduce reliance on foreign pharmaceutical production, and bolster domestic supply chain resilience amid rising tariffs and reshoring investments.

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.

Eli Lilly’s investigational, once-daily oral GLP-1 receptor agonist orforglipron produced a 12% body weight reduction in a Phase III trial, slightly lower than Novo Nordisk’s Wegovy.

The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 outlook on the strength of key pharmaceutical products.

Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one year and older.

XtalPi and DoveTree collaborate on a groundbreaking $6 billion drug discovery partnership, merging AI technology with biological expertise to tackle complex diseases.

Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the public domain.

Currax Pharmaceuticals expands its impactful campaigns, showcasing real patient stories to empower those battling obesity and food cravings across the U.S.

The industry is facing calls to reduce prices while also bracing for increased tariffs.